Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M, et al. Diabetes, Obesity and Metabolism 2022;24:1553-1564.
What it found
People who had lost a mean 17.3% on semaglutide regained 11.6 percentage points in the year after stopping, ending 5.6% below their starting weight. Most improvements in blood pressure, blood sugar and blood fats moved back towards baseline.
Limitations
Exploratory analysis of a subset of STEP 1 participants from selected countries. Lifestyle support also stopped at week 68.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.